Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

B. Daly, Mary; Pal, Tuya; P. Berry, Michael; S. Buys, Saundra; Dickson, Patricia; M. Domchek, Susan; Elkhanany, Ahmed; Friedman, Susan; Goggins, Michael; L. Hutton, Mollie; , CGC; Y. Karlan, Beth; Khan, Seema; Klein, Catherine; Kohlmann, Wendy; , CGC; W. Kurian, Allison; Laronga, Christine; K. Litton, Jennifer; Mak, Julie; , LCGC; S. Menendez, Carolyn; D. Merajver, Sofía; S. Norquist, Barbara; Offit, Kenneth; J. Pederson, Holly; Reiser, Gwen; , CGC; Senter-Jamieson, Leigha; , CGC; M. Shannon, Kristen; Shatsky, Rebecca; Visvanathan, Kala; N. Weitzel, Jeffrey; Wick, Myra; B. Wisinski, Kari; B. Yurgelun, Matthew; Darlow, Susan; A. Dwyer, Mary

doi:10.6004/jnccn.2021.0001

Public

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published in Journal of the National Comprehensive Cancer Network • Jan 6, 2021

Authors:

Mary B. Daly

Tuya Pal

Michael P. Berry

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling a...

Subject

Medicine

Oncology

Ovarian cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!